The podcast discusses the unexpected departure of Novo Nordisk's CEO, Lars Jorgensen, despite the company's financial success with drugs like Ozempic and Wegovy. It explores the reasons behind his removal, including increasing competition from Eli Lilly's weight loss drug, ZepBound, and disappointing clinical trial results for Novo's new drug, Kagrasema. The podcast also delves into Novo Nordisk's unique corporate structure, overseen by a non-profit foundation, and the implications of bringing back a previous CEO to the drugmaker's board of directors amidst the competitive landscape of the pharmaceutical industry.
